These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15496501)

  • 1. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.
    Pisano C; Aulicino C; Vesci L; Casu B; Naggi A; Torri G; Ribatti D; Belleri M; Rusnati M; Presta M
    Glycobiology; 2005 Feb; 15(2):1C-6C. PubMed ID: 15496501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
    Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
    Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
    Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic potency of vitamin E.
    Miyazawa T; Tsuzuki T; Nakagawa K; Igarashi M
    Ann N Y Acad Sci; 2004 Dec; 1031():401-4. PubMed ID: 15753181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
    Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY
    Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic properties of gold nanoparticles.
    Mukherjee P; Bhattacharya R; Wang P; Wang L; Basu S; Nagy JA; Atala A; Mukhopadhyay D; Soker S
    Clin Cancer Res; 2005 May; 11(9):3530-4. PubMed ID: 15867256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparanase, heparin and the coagulation system in cancer progression.
    Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
    Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
    Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
    Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
    Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
    Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.